We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Tampilkan postingan dengan label First. Tampilkan semua postingan
Tampilkan postingan dengan label First. Tampilkan semua postingan

Minggu, 04 Desember 2011

First 3D Movie of Orgasm in the Female Brain

AppId is over the quota

An orgasm has now been imaged in 3D video in the brain as it happens - and for possibly the first time in the history of science, women came first.

The video, which was presented at the recent Society for Neuroscience conference in Washington, D.C., is the first to look at the exact order in which women's brain regions are activated in the progression that culminates in sexual climax. The findings have not yet been peer reviewed for publication.

While this may seem like a silly line of research, in fact, understanding how the brain experiences the most pleasurable sensations may be essential for figuring out what underlies conditions in which desire and motivation go awry, like addiction and depression.

Lead author Barry Komisaruk, professor of psychology at Rutgers University, imaged brain activity in several women who were able to masturbate to orgasm in the decidedly unsexy atmosphere of a functional MRI machine. (Orgasm was achieved by either manual stimulation or use of a "passive dildo" in the form of a Lucite rod; vibrators contain metal, which cannot be placed in magnetic scanners.)

MORE: Mind Reading: What We Can Learn From the Dutch About Teen Sex

Komisaruk discovered activity in more than 80 regions of the brain, including the prefrontal cortex, which is involved in higher-order thinking, and which earlier imaging of the female orgasm by Dutch researchers had found to be inactive. "There's an apparent contradiction in the literature," says Komisaruk. "The group in Holland says that the frontal cortex goes down in activity during orgasm and we see that it goes up."

That could be due to differences in technical scanning, Komisaruk says. Or, a more interesting reason may involve the fact that in the Dutch study, sexual stimulation was applied by the women's partners, rather than themselves. "It could be different [because] women orgasm-inducing in themselves may involve executive control characteristic of the prefrontal cortex, whereas in partner-induced stimulation, women may surrender to their partner and that could be the basis for the reduction in activity," he explains.

The sequence of brain activity itself is telling. First, not surprisingly, activation is seen in the sensory regions of the brain that map the genitals. Earlier research by Komisaruk's group showed that nipple stimulation also agitated this sensory region, helping explain why it can be erotic.

Next, a region called the insula lights up. "Not only is [the insula] active during orgasm, it's also active in response to pain," says Komisaruk, explaining that brain imaging is difficult to interpret because "activation" can mean different things in different brain cells. If inhibitory neurons are active, this actually reduces the signaling of other neurons - and could mean something is being prevented rather than processed. "We see strong inhibitory interaction between orgasm and pain," he says. "During orgasm, women are much less sensitive to pain."

Komisaruk notes that facial expressions during orgasm (the "O face") are often indistinguishable from those made in pain, and suggests this may be explained by activity in the insula.

MORE: The Female Erotic Brain, Mapped

Next, the anterior cingulate, an area related to the insula, lights up before the action moves to the amygdala. Although it is best known for processing fear-related information, the amygdala is actually involved in all types of emotion - and may provide some of the intense positive emotion typically experienced during orgasm.

Activity is seen next in the hippocampus, which processes memories and may be involved either in sexual fantasy or in recording the experience or both. The hippocampus is also able to activate many brain regions at once, which may underlie its role in both orgasm and seizure. "The hippocampus is often involved in epileptic seizure activity," says Komisaruk. "There's a lot of similarity between seizures and orgasms in the sense that they involve many brain regions concurrently."

After the hippocampus, Komisaruk saw activity in the prefrontal cortex, the region involved in planning, abstract thought and behavior control. He's currently doing a study comparing partner-induced self-stimulated to orgasm and see if he can resolve the question of why some studies show activation here and others don't.

Following the cortex, activation flowed through a region involved in movement and muscle tension, which occurs during orgasm. Next, the hypothalamus came online. This region releases oxytocin, the notorious "love hormone" involved in social and emotional bonding and connection.

Finally, it's on to the brain's "pleasure center", for the peak experience of orgasm, which likely involves release of dopamine in the highly activated nucleus accumbens.

And then, the brain goes quiet.

MORE: Real-Time Video: First Look at a Brain Losing Consciousness Under Anesthesia

Maia Szalavitz is a health writer at TIME.com. Find her on Twitter at @maiasz. You can also continue the discussion on TIME Healthland's Facebook page and on Twitter at @TIMEHealthland.



News



Debt Financing

Kamis, 13 Oktober 2011

WHO: New TB Cases Worldwide Drop for the First Time

AppId is over the quota
AppId is over the quota

Number of new cases of tuberculosis in 2010, down from a high of 9 million in 2005, according to the World Health Organization (WHO) — marking the first drop in new infections worldwide. Deaths from TB also fell to 1.4 million last year, from 1.8 million deaths in 2003. Efforts to find and treat people with TB have paid off, with many countries, including Brazil, Cambodia and Uganda, slashing mortality rates over the last two decades. China has made substantial progress — its TB death rates have dropped nearly 80% from 1990 to 2010. But a $1 billion shortfall in 2012 funding to fight TB jeopardizes these advances, especially as drug-resistant forms of the disease spread, the WHO said. Only 16% of patients with multidrug-resistant tuberculosis received treatment in 2010. [via WHO]



News



Debt Financing

80 percent of US boys use condoms the first time

AppId is over the quota
AppId is over the quota
CHICAGO (AP) — A surprising 80 percent of teenage boys say they are using condoms the first time they have sex, a government survey found in a powerful sign that decades of efforts to change young people's sexual behavior are taking hold.

But another promising trend — a drop since the 1980s in the number of teenagers having sex — has leveled off.

Boys' condom use may mean they are taking more responsibility for contraception or they are protecting themselves from sexually transmitted diseases, experts say. Or, as one young man said, girls may be drawing the line.

"I'm not sure how much of this is guys thinking they need to use a condom or girls insisting they use a condom," said 17-year-old Olivier Vanasse of Princeton, N.J. "I'd be hesitant to give guys credit for coming up with this on their own."

The study, released Wednesday, is based on interviews with about 4,700 teenagers, ages 15 to 19, conducted from 2006 through 2010. It shows the percentage of boys who said they used condoms the first time they had sex climbed from 71 percent in 2002 to 80 percent in the new survey. In 1988, 55 percent of boys said they used a condom during their first sexual intercourse.

"It comes as a general surprise to people that teenagers in general and teen boys in particular can behave responsibly when it comes to making decisions about sex," said Bill Albert, spokesman for the National Campaign to Prevent Teen and Unplanned Pregnancy. "I think it is surprising."

The survey suggests that condom use continues. Asked if they used a condom the last time they had sex in the previous three months, 75 percent said they did, an increase from 71 percent in 2002.

"We don't think it's a stupid thing to do anymore," said Vanasse, a high school senior and staff writer for www.sexetc.org, a project of Rutgers University's Answer, a national sex education organization. "It's just accepted as common sense that you should be using a condom if you're going to be having sex."

Overall, about 43 percent of girls and 42 percent of boys report ever having vaginal intercourse, a rate that is statistically unchanged since 2002. The rates had been declining steadily since 1988, when 51 percent of girls and 60 percent of boys reported that they had had sex.

Albert said those findings also explode myths about teen sex.

"There's the notion that all teenagers are doing it, and that's not the case. In fact, less than half said they've had sex," he said. "And there's no gender gap between the teen boys and the teen girls. There's a myth that guys are out on the prowl, and that's not supported by this data."

Less sex and more contraception are driving down teen births, he said. The U.S. teen birth rate in 2009 — 39 births per 1,000 females — was nearly 40 percent lower than the peak in 1991. It's still a dramatically higher birth rate than in Western Europe, where birth control is less expensive and more accessible to teens.

The new study contains more encouraging news. For the first time, there was no racial difference in the percentage of girls reporting they had had sex. In the past, black females were more likely than whites to be sexually experienced.

"That's due to a drop in black females who are sexually experienced," said the study's lead author, Gladys Martinez, a demographer for the government's National Center for Health Statistics.

Other findings:

— Teens were less likely to have had sex if they lived with both parents, if their mothers hadn't been teen moms themselves, or if their mothers were college graduates.

— Most teens — 70 percent of girls and 56 percent of boys — had their first sex with someone with whom they were "going steady."

— A minority — 16 percent of girls and 28 percent of boys — had their first sex with someone they just met or with whom they were "just friends."

Some teenage girls are trying newer contraceptive methods, even the first time they have sex. A small but growing proportion of girls — 6 percent in the new survey, compared with 2 percent in 2002 — reported using long-acting hormonal methods such as injectable birth control, contraceptive patches or the new contraceptive ring.

The finding on teenage boys' condom use heartened proponents of sex education.

"Boys have really stepped up to the plate in the last 20 years. We've included them in the conversation about teen sex and have seen them as able to be responsible actors, and they've done it for us," said Linda Lindberg, a senior research associate for the Guttmacher Institute. "There's been some shift from the double standard of teaching boys not to ask for sex and teaching girls to say no."

She said it was too soon to see any effect from the Obama administration's move away from abstinence-only sex education to programs that teach pregnancy prevention.

___

Online:

Report: http://www.cdc.gov/NCHS/

___

AP Medical Writer Carla K. Johnson can be reached at http://www.twitter.com/CarlaKJohnson

Associated Press

Technology



News

'First ever' fall in global TB

AppId is over the quota
AppId is over the quota
11 October 2011 Last updated at 14:28 GMT By Matt McGrath Science reporter, BBC World Service TB testing A mucus sample is tested for TB The number of people falling ill with tuberculosis has declined for the first time, according to the World Health Organization.

New figures show the global death toll has also fallen, to its lowest level in a decade, with major headway made in China, Brazil, Kenya and Tanzania.

But the WHO warns that a lack of funds threatens progress, especially in relation to multi-drug resistant TB.

UN Secretary-General Ban Ki-moon said there was no cause for complacency.

According to the WHO, the figures represent a significant milestone in the battle against a disease that infects one third of the world's population, although only a small proportion become sick as a result.

The number of people who died from tuberculosis peaked at 1.8 million people in 2003; by 2010 this had declined to 1.4 million.

Challenges ahead

Spectacular progress was made in China, said the WHO, where the death rate fell by almost 80% between 1990 and 2010. In Kenya and Tanzania there has also been a substantial decline in the last decade after a peak linked to the HIV epidemic.

"This is major progress. But it is no cause for complacency," the UN Secretary-General said in a statement.

"Too many millions still develop TB each year, and too many die. I urge serious and sustained support for TB prevention and care, especially for the world's poorest and most vulnerable people."

Continue reading the main story Tuberculosis is an infectious disease that usually affects the lungsIt is transmitted via droplets from the lungs of people with the active form of the disease Symptoms of TB include coughing, chest pains, weakness, weight loss, fever and night sweatsTuberculosis is treatable with a course of antibioticsMoney is the key to the current progress, said the WHO, particularly domestic funding in larger countries like Brazil.

But the organisation warned that substantial challenges lie ahead, with a projected gap in funding of $1bn for 2012.

Another problem is the multi-drug resistant form of the disease.

A new rapid test is revolutionising diagnosis but there is a concern that only a small percentage of the people diagnosed with multi-drug resistant TB are receiving treatment.



Debt Financing



Career Advisor

Senin, 10 Oktober 2011

FDA Approves Juvisync, First Combo Pill to Treat Diabetes and High Cholesterol

AppId is over the quota
AppId is over the quota

The U.S. Food and Drug Administration approved on Friday the first combination pill to treat Type 2 diabetes and high cholesterol.

The new pill called Juvisync, made by Merck, combines the company's most popular diabetes drug, Januvia (sitagliptin), and its cholesterol-lowering statin Zocor (simvastatin). The AP called the pill a "probable blockbuster," predicting that it will appeal to millions of patients with diabetes who are not currently taking a statin.

Many of the estimated 25 million Americans who have Type 2 diabetes also have high cholesterol — in part because both conditions are related to obesity — a dangerous combination that increases patients' risk of heart disease, stroke and kidney disease.

The American Diabetes Association recommends that patients with diabetes who have heart disease or are over age 40 to add a statin to their daily regimen. Patients who follow medication guidelines end up taking multiple pills a day to control blood sugar, cholesterol and blood pressure. But many other patients — up to 4 million diabetes patients over 40 according to Merck scientists, the AP reported — are not taking statins.

Juvisync, which promises to streamline patients' required medications, will sell for the same price as Januvia alone, about $215 per month. Zocor in its generic form costs about $30 a month.

The new pill will be available in six different dosage strengths to accommodate patients with varying disease. The most common side effects of the pill include upper respiratory infection, stuffy or runny nose, headache, sore throat, muscle and stomach pain, nausea and constipation.

Last year, Januvia had sales of $2.4 billion. So far this year, it's brought in $1.5 billion. Merck's Janumet, another combo pill that combines Januvia with the the generic diabetes drug metformin, had sales of $626 million in the first half of 2011.

Meredith Melnick is a reporter at TIME. Find her on Twitter at @MeredithCM. You can also continue the discussion on TIME's Facebook page and on Twitter at @TIME.



News



Debt Financing

Jumat, 07 Oktober 2011

FDA approves first diabetes-cholesterol combo pill

AppId is over the quota
AppId is over the quota
TRENTON, N.J. (AP) — The first combination pill for the millions of people with the dangerous combination of diabetes and high cholesterol won U.S. approval Friday, offering convenience — and savings — to patients taking multiple pills.

Juvisync, a probable blockbuster developed by Merck & Co. Inc., will be launched in a few weeks. It combines Merck's Type 2 diabetes pill Januvia with Zocor, a former Merck blockbuster in the widely used class of cholesterol drugs called statins.

The combination pill will sell for the same price as Januvia alone, about $215 per month. Generic versions of Zocor cost roughly $30 a month.

That should make Juvisync attractive for the millions of diabetics currently not taking a statin. Guidelines from the American Diabetes Association recommend that diabetics who have heart disease or are over age 40 take a statin pill daily.

"This provides a way to simplify their regimen and improve adherence," said Dr. Susan Spratt, an endocrinologist at Duke University Medical Center.

Spratt said many diabetes patients are taking six or more pills a day, including different types of pills for diabetes, blood pressure and high cholesterol. It can be hard to consistently take them all at the right time, and even with health insurance, patients' out-of-pocket costs for their medications and diabetes testing supplies can be very high.

"Anything to reduce the cost is going to be helpful to patients," Spratt said, adding, "When you improve medication adherence, you actually lower health care costs because patients don't end up in the ER or the hospital."

Merck shares rose 37 cents to $31.79 in late-afternoon trading, after rising nearly 3 percent.

In Type 2 diabetes, the body either does not produce enough of the hormone insulin or does not use it efficiently, allowing excess sugar, or glucose, to accumulate in the blood. Over time, that damages blood vessels and crucial organs.

Many of the more than 25 million U.S. diabetes patients also have high cholesterol, partly because both conditions often are linked to being overweight. The combination increases risk of heart disease, stroke, kidney disease and other chronic conditions. Diabetics also are at risk of blindness, amputations from wounds that do not heal and heart attacks.

Despite those dangers, Merck scientists estimate that up to 4 million diabetes patients over 40 are not following the medication recommendation.

"Perhaps one third of the nation's eligible patients with type 2 diabetes are not being treated with a statin, so here's a convenient tool for doctors to target glucose as well as cholesterol levels," Dr. Sethu Reddy, Merck's director of clinical affairs for diabetes, said in a statement.

Juvisync will be available in six different dosage strengths, to accommodate patients with varying levels of cholesterol and diabetes. Common side effects of the drug include stuffy nose and sore throat, headache, muscle and stomach pain.

The approval revives Zocor, which had been Merck's top-selling medicine before it got generic competition in June 2006. It's now available in nearly a dozen generic forms as simvastatin.

Januvia, Merck's third-best-selling drug, was approved in October 2006. It was the first diabetes drug in a new class called DPP-4 inhibitors that now includes Bristol-Myers Squibb Co.'s Onglyza and Tradjenta, made by Eli Lilly & Co. and Boehringer Ingelheim.

The drugs work by making the body produce more insulin after meals, to reduce levels of glucose in the blood, and by limiting the amount of glucose made by the liver.

Januvia brought in $1.5 billion in the first six months of this year and had sales of $2.4 billion last year. Merck already sells a pill that combines Januvia with a widely used generic diabetes pill, metformin. That combo pill, called Janumet, had sales of $626 million in the first half of this year.

With Merck's top seller, asthma and allergy drug Singulair, getting generic competition next August, the Januvia franchise becomes even more important for the company, which is the world's third-biggest drugmaker by revenue.

Merck, based in Whitehouse Station, N.J., is planning to seek approval of Juvisync in many other countries in the near future, according to spokeswoman Pam Eisele.

___

AP Business Writer Matt Perrone in Washington contributed to this story.

Associated Press

Technology



News

Jumat, 23 September 2011

First European Embryonic Stem Cell Trial Gets Green Light

AppId is over the quota
AppId is over the quota

Health authorities in the U.K. approved on Thursday Europe's first clinical trial involving embryonic stem cells.

Surgeons at Moorfields Eye Hospital in London will treat 12 patients with Stargardt's macular dystrophy, a major cause of blindness in young people. Patients with Stargardt's gradually lose retinal pigment epithelial cells, or RPE cells, which are essential for maintaining the proper environment that encourages retinal cells to grow.

Patients in the U.K. trial will receive RPE cells grown from human embryonic stem cells. This is the second human trial to use such cells; the first was approved by the U.S. Food and Drug Administration (FDA) last November, which we described here. In both studies, the cells will be made by Massachusetts-based Advanced Cell Technology (ACT).

The purpose of the trial is to establish the safety of the treatment, so the dozen enrolled patients are at the most advanced stages of the incurable disease. They will receive anywhere from 50,000 to 200,000 cells, injected directly into the eye, behind the retina. Doctors expect that the transplanted cells will then start to grow in their new environment, replacing the diseased and dying ones that have robbed the patients of their vision.

The eye is a good site for testing such a treatment, since it is relatively protected from the immune system; the new cells may therefore be protected from destruction by overzealous defensive cells. The isolated nature of the eye's vitreous cavity, where the cells are injected, also makes it relatively easy for doctors to destroy the transplanted RPE cells should something go wrong, such as if the cells should start forming tumors or migrate to other areas.

The eye trials follow the first ever approved human trial of an embryonic stem cell based-therapy, approved in January 2009 in the U.S. to treat spinal cord injury. The FDA put that trial on hold after some animals receiving the stem cells developed cysts, but the company conducting the trial, Geron, provided additional safety data and new tests for detecting the unusual growths. Last summer the trial was once again allowed to move forward.

Embryonic stem cells could become an important source of replacement cells for a number of different diseases, including diabetes and Parkinson's. As Dr. James Barinbridge, a retinal surgeon at Moorfields and the UCL Institute of Ophthalmology, told the U.K.'s Guardian, "The ability to regenerate retinal cells from stem cells in the laboratory has been a significant advance and the opportunity to help translate such technology into new treatments for patients is hugely exciting. Testing the safety of retinal cell transplantation in this clinical trial will be an important step towards achieving this aim."

Alice Park is a writer at TIME. Find her on Twitter at @aliceparkny. You can also continue the discussion on TIME's Facebook page and on Twitter at @TIME.



View the original article here



Peliculas Online